Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Tolar, Jakub  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
3
Jung JP, Lin W-H, Riddle MJ, Tolar J, Ogle BM. A 3D in vitro model of the dermoepidermal junction amenable to mechanical testing. J Biomed Mater Res A. 2018.
A
Dieter K, Niebergall-Roth E, Daniele C, Fluhr S, Frank NY, Ganss C, Kiritsi D, McGrath JA, Tolar J, Frank MH, et al. ABCB5 mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa. Cytotherapy. 2023.
Lee CAA, Wu S, Chow YTing, Kofman E, Williams V, Riddle M, Eide C, Ebens CL, Frank MH, Tolar J, et al. Accelerated Aging and Microsatellite Instability in Recessive Dystrophic Epidermolysis Bullosa-Associated Cutaneous Squamous Cell Carcinoma. J Invest Dermatol. 2024.
Oever MJVanden, Tolar J. Advances in understanding and treating dystrophic epidermolysis bullosa. F1000Prime Rep. 2014;6:35.
Saha A, Palchaudhuri R, Lanieri L, Hyzy S, Riddle MJ, Panthera J, Eide C, Tolar J, Panoskaltsis-Mortari A, Gorfinkel L, et al. Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate conditioned Fanconi anemia mice. Blood. 2024.
Osborn MJ, Webber BR, McElmurry RT, Rudser KD, DeFeo AP, Muradian M, Petryk A, Hallgrimsson B, Blazar BR, Tolar J, et al. Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. J Inherit Metab Dis. 2016.
B
Osborn MJ, Newby GA, McElroy AN, Knipping F, Nielsen SC, Riddle MJ, Xia L, Chen W, Eide CR, Webber BR, et al. Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs. J Invest Dermatol. 2019.
Tolar J, Wagner JE. A Biologic Velcro Patch. N Engl J Med. 2015;372(4):382-384.
C
Matson JPeter, Dumitru R, Coryell P, Baxley RM, Chen W, Twaroski K, Webber BR, Tolar J, Bielinsky A-K, Purvis JE, et al. Correction: Rapid DNA replication origin licensing protects stem cell pluripotency. Elife. 2019;8.
Dieter K, Niebergall-Roth E, Daniele C, Fluhr S, Frank NY, Ganss C, Kiritsi D, McGrath JA, Tolar J, Frank MH, et al. Corrigendum to ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa [Cytotherapy 25 (2023) 782-788/1562]. Cytotherapy. 2023;25(9):1016.
D
Webber BR, Iacovino M, Choi SHo, Tolar J, Kyba M, Blazar BR. DNA methylation of Runx1 regulatory regions correlates with transition from primitive to definitive hematopoietic potential in vitro and in vivo. Blood. 2013.
F
Webber BR, Tolar J. From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa. Mol Ther. 2014.
Popp CM, Miller WC, Eide CR, Tolar J. Future Applications of 3D Bioprinting: A promising technology for treating recessive dystrophic epidermolysis bullosa. Exp Dermatol. 2021.
I
Wang C, Gu C, Popp C, Vashisth P, Mustfa SAhmad, Martella DAlessandro, Spiteri C, McLennan S, Sun N, Riddle M, et al. Integrating Porous Silicon Nanoneedles within Medical Devices for Nucleic Acid Nanoinjection. ACS Nano. 2024.
L
Tolar J, Tolar M. A living band-aid for epidermolysis bullosa. Blood Transfus. 2015;13(1):1-2.
M
Oever MVanden, Muldoon D, Mathews W, McElmurry R, Tolar J. miR-29 Regulates Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa. J Invest Dermatol. 2016.
N
Yuan C, Bothun ED, Hardten DR, Tolar J, McLoon LK. A novel explanation of corneal clouding in a bone marrow transplant-treated patient with Hurler syndrome. Exp Eye Res. 2016.
P
Stefanski HE, Xing Y, Nicholls J, Jonart L, Goren E, Taylor PA, Mills AA, Riddle M, McGrath J, Tolar J, et al. P63 targeted deletion under the FOXN1 promoter disrupts pre-and post-natal thymus development, function and maintenance as well as induces severe hair loss. PLoS One. 2022;17(1):e0261770.
Mack M, Wendelschafer-Crabb G, McAdams B, Hordinsky M, Kennedy W, Tolar J. Peripheral Neuro-Immune Pathology in Recessive Dystrophic Epidermolysis Bullosa. J Invest Dermatol. 2014.
Nevala-Plagemann C, Lee C, Tolar J. Placenta-based therapies for the treatment of epidermolysis bullosa. Cytotherapy. 2015.
Petrof G, Lwin SM, Martinez-Queipo M, Abdul-Wahab A, Tso S, Mellerio JE, Slaper-Cortenbach I, Boelens JJ, Tolar J, Veys P, et al. Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children With Recessive Dystrophic Epidermolysis Bullosa. J Invest Dermatol. 2015.
Hippen KL, Watkins B, Tkachev V, Lemire AM, Lehnen C, Riddle MJ, Singh K, Panoskaltsis-Mortari A, Vanhove B, Tolar J, et al. Preclinical testing of anti-human CD28 Fab' antibody in a novel nonhuman primate (NHP) small animal rodent model of xenogenic graft-versus-host disease (GVHD). Transplantation. 2016.
Ramos TLopes, Bolivar-Wagers S, Jin S, Thangavelu G, Simonetta F, Lin P-Y, Hirai T, Saha A, Koehn BH, Su LL, et al. Prevention of acute GVHD disease using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T-cells in vivo. Blood. 2022.
S
Lund TC, Patrinostro X, Kramer AC, Stadem P, Higgins L, Markowski TW, Wroblewski MS, Lidke DS, Tolar J, Blazar BR. sdf1 expression reveals a source of perivascular-derived mesenchymal stem cells in zebrafish. Stem Cells. 2014.